Analysts meticulously research for up to 3-4 months to put together one suite of reports, a MedSuite, which is a comprehensive analysis of a group of healthcare markets. This MedCore is one portion of that analysis which focuses on the Dental Soft Tissue Regeneration market segment and provides detailed analysis on the Market Size, Unit Sales, ASPs, and Company Market Shares.
Dental Soft Tissue Regeneration Market Insights
The vast majority of unit sales were xenograft products produced by Geistlich and Botiss, and the remainder consisted mostly of AlloDerm®, which is distributed by BioHorizons. Even if regulations surrounding the use of human tissue for soft tissue regeneration impede sales of these types of products throughout Europe, within the dental indication specifically, the regulatory hurdles are slightly less pronounced.
Some dentists in this market are using these devices to increase biotype and soft tissue thickness around implants. The number of dental regenerative matrix units sold is partly correlated with the number of dental implant procedures in a given country. This explains why, population differences aside, unit sales in Germany and Italy were slightly higher than in France, and significantly higher than in the United Kingdom.
The EU dental soft tissue regeneration market was valued at €7.3 million in 2019. The market value is expected to increase and reach somewhere in between €8.5 and €9.9 million by 2026, depending on the impact of COVID19 on the overall market.
Interested In The COVID19 Impact on the Dental Market in the US?
When inquiring about this research, ask your product consultant about the Complimentary COVID Impact Whitepaper.
Dental Soft Tissue Regeneration Market Insights
The vast majority of unit sales were xenograft products produced by Geistlich and Botiss, and the remainder consisted mostly of AlloDerm®, which is distributed by BioHorizons. Even if regulations surrounding the use of human tissue for soft tissue regeneration impede sales of these types of products throughout Europe, within the dental indication specifically, the regulatory hurdles are slightly less pronounced.
Some dentists in this market are using these devices to increase biotype and soft tissue thickness around implants. The number of dental regenerative matrix units sold is partly correlated with the number of dental implant procedures in a given country. This explains why, population differences aside, unit sales in Germany and Italy were slightly higher than in France, and significantly higher than in the United Kingdom.
The EU dental soft tissue regeneration market was valued at €7.3 million in 2019. The market value is expected to increase and reach somewhere in between €8.5 and €9.9 million by 2026, depending on the impact of COVID19 on the overall market.
Interested In The COVID19 Impact on the Dental Market in the US?
When inquiring about this research, ask your product consultant about the Complimentary COVID Impact Whitepaper.
Table of Contents
LIST OF FIGURESLIST OF CHARTSPROCEDURE NUMBERSABBREVIATIONS
RESEARCH METHODOLOGY
IMPACT OF COVID-19 ON THE EUROPE DENTAL SOFT TISSUE REGENERATION MARKET
EUROPE DENTAL SOFT TISSUE REGENERATION MARKET
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Botiss Biomaterials
- Geistlich
- Allergan
- Orthocell
- Zimmer Biomet
